Security Reports
Global Blood Therapeutics

Global Blood Therapeutics

This is a preliminary report on Global Blood Therapeutics’s security posture. If you want in-depth, always up-to-date reports on Global Blood Therapeutics and millions of other companies, consider booking a demo with us. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.

UpGuard Security Rating

${grade.letter}
${cstarScore}
/ 950
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Global Blood Therapeutics has good security practices.
Company
Global Blood Therapeutics
Employees
Location
CEO
Ted W. Love, M.D.
Last updated
Last updated
Industries
Last updated today

Security report for Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Global Blood Therapeutics Data Breaches and Security News

Relevant news, breaches and security articles relating to Global Blood Therapeutics.
No recent security news.

More security reports

Compare Global Blood Therapeutics's security performance with other companies.
Deliver icon

Sign up to our newsletter

Get the latest curated cybersecurity news, breaches, events and updates in your inbox every week.
Abstract shapeAbstract shape
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
Website Security scan resultsWebsite Security scan ratingAbstract shape

Book a free demo

Book a free, personalized onboarding call with one of our cybersecurity experts.